Resumen de acción HIK
Hikma Pharmaceuticals PLC desarrolla, fabrica, comercializa y vende una gama de productos farmacéuticos genéricos, de marca y con licencia. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 6/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 3/6 |
| Salud financiera | 4/6 |
| Dividendos | 5/6 |
Recompensas
Análisis de riesgos
Competidores de Hikma Pharmaceuticals PLC
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | UK£18.45 |
| Máximo en las últimas 52 semanas | UK£21.65 |
| Mínimo de 52 semanas | UK£17.11 |
| Beta | 0.44 |
| 1Cambio en 1 mes | -7.61% |
| Variación en 3 meses | -8.66% |
| Cambio de 1 año | 5.07% |
| 3Variación en 3 años | -19.36% |
| Variación en 5 años | -5.87% |
| Variación desde la OPV | 554.26% |
Noticias y actualizaciones recientes
Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark
Nov 11
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Oct 24Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 11Recent updates
Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark
Nov 11Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Oct 24Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 11Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 01Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued
Dec 12Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Sep 01Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price
Jun 02Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Feb 21Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Sep 27Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 24These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well
Jun 06Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Feb 26Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price
Dec 01Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?
Nov 11Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?
Sep 02Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Aug 09Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate
May 21Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly
May 03It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year
Apr 16How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?
Apr 13Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend
Mar 14Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 28Rentabilidad de los accionistas
| HIK | GB Pharmaceuticals | Mercado GB | |
|---|---|---|---|
| 7D | 2.0% | -2.3% | 0.7% |
| 1Y | 5.1% | -2.8% | 6.1% |
Rentabilidad vs. Industria: HIK superó a la industria UK Pharmaceuticals, que obtuvo un rendimiento del -2.8% el año pasado.
Rentabilidad vs. Mercado: HIK obtuvo unos resultados inferiores a los del mercado UK, que fueron del 6.1% el año pasado.
Volatilidad de los precios
| HIK volatility | |
|---|---|
| HIK Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Precio estable de las acciones: HIK no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de HIK (3%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1978 | 9,100 | Riad Mishlawi | www.hikma.com |
Hikma Pharmaceuticals PLC desarrolla, fabrica, comercializa y vende una gama de productos farmacéuticos genéricos, de marca y bajo licencia. Opera a través de tres segmentos: Inyectables, Genéricos y de Marca. El segmento de inyectables suministra productos genéricos inyectables principalmente para su uso en hospitales.
Resumen de fundamentos de Hikma Pharmaceuticals PLC
| Estadísticas fundamentales de HIK | |
|---|---|
| Capitalización bursátil | UK£4.09b |
| Beneficios(TTM) | UK£225.36m |
| Ingresos (TTM) | UK£2.39b |
18.2x
Ratio precio-beneficio (PE)1.7x
Ratio precio-ventas (PS)¿Está HIK sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de HIK | |
|---|---|
| Ingresos | US$3.02b |
| Coste de los ingresos | US$1.57b |
| Beneficio bruto | US$1.45b |
| Otros gastos | US$1.16b |
| Beneficios | US$285.00m |
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 1.29 |
| Margen bruto | 47.99% |
| Margen de beneficio neto | 9.45% |
| Ratio deuda/patrimonio | 53.2% |
¿Cómo se ha desempeñado HIK a largo plazo?
Ver rendimiento histórico y comparativa